Lynn Oaks Compounding Pharmacy, Thousand Oaks, CA
Is Lynn Oaks Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Lynn Oaks Compounding Pharmacy hold a California pharmacy license?
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.
Has Lynn Oaks Compounding Pharmacy had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jun 9, 2023), 1 untitled letter (Dec 8, 2022), 1 state referral letter (Jun 9, 2023) and 1 FMD-145 letter (Jun 9, 2023) for Lynn Oaks Compounding Pharmacy. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended” dated Mar 4, 2026, case AC 7930 on license PHY 55673. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Lynn Oaks Compounding Pharmacy
- Location
- Thousand Oaks, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 9, 2023
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 7 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Lynn Oaks Compounding Pharmacy, a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Jun 9, 2023 | State referral letter | State Referral Letter Issued 06/09/2023 | FDA copy (archived) |
| Jun 9, 2023 | Warning letter close-out | Warning Letter Closeout Issued 06/09/2023 | Not linked by FDA |
| Jun 9, 2023 | FMD-145 letter | FMD-145 Letter Issued 06/09/2023 | Not linked by FDA |
| Dec 8, 2022 | Untitled letter | Untitled Letter Issued 12/08/2022 | FDA copy (archived) |
| Apr 15, 2022 | Form 483 | 483 Issued 04/15/2022 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Lynn Oaks Compounding Pharmacy, Thousand Oaks, CA (FEI number 3021028639), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 15, 2022 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3021028639 | 1168587 |
Form 483s FDA has published for this site
- Apr 15, 2022: Form 483 to Lynn Oaks Compounding Pharmacy, published Nov 28, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 30, 2022 to Apr 15, 2022: 7 observations
- Firm on the cover
- Lynn Oaks Compounding Pharmacy, ESS 2220 Lynn Rd Ste 101, Thousand Oaks, CA 91360-8018
- Establishment type on the cover
- Producer of Non Sterile Drug Products
- FDA district office on the cover
- Not read
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You produced hazardous drugs without providing adequate containment, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically,
Your firmly routinely produces hazardous/highly potent non-sterile drug products (containing Digoxin. chlorambucil. tacrolimus, zonisamide. tretinoin or hormones, without producing adequate containment. cleaning or utensils and work surfaces to prevent cross-contamination. During the period from 1/1/2022 to 3/31/2022, your firm produced <Redacted B4> drug products with hazardous/highly potent drugs accounting for approximately <Redacted B4>% of all drug products.
A . On 3/30/202, we observed your non-sterile technician spill powders onto the surfaces of the Biological Safety Cabinet <Redacted B4> and the balance <Redacted B4> inside the cabinet during processing of Zonisamide, 20mg/ml, Rx <Redacted B4> a hazardous drug. ...
Observation 2
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically.
A) Analytical Standard Digoxin, Batch Number <R ed acted B4> purch ase d from <Redacted B4> was used in producing Home Hospice EOL SUS as the active pharmaceutical ingredient. D uring the p eriod of January to March 2022, your firm produced this drug for patient-specific presc
riptions for th e follow ing <Redacted B4>, <Reda cted B4> <Redact ed B4> and <Redacted B4>.
B)
<Redacted B4> <Redacted B4> was used in producing all water-containing drug products. During the period of January to March, 2022, you produced Pantoprazole 2mg/ml GTUBE Suspension for 3 patient-specific prescriptions, Rx <Redacted B4>, Rx <Redacted B4>, and Rx <Redacted B4> and Tetracaine 6% Topical Solution, Rx <Redacted B4> for office use using filtered water.
Observation 3
Vermin was observed in your production area.
Specifically.
We observed that a living insect was crawling on the exterior surface of the biological safety cabinet on the left side on 3/30/2022 in the "compounding room". The sliding door entry to the "compounding room" is always opened to the outside retail pharmacy area when producing non-hazardous drugs, and is closed only when producing hazardous drugs. For example, the door in the "compounding room" was opened while your non-sterile technician produced DICL/KETOLIDO 2.5/10/7.5 Cream on 4/1/2022 and Clarithromycin 375 mg. Rx <Redacted B4> Capsule on 4/5/2022.
Observation 4
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Specifically.
You did not test non-sterile topical preparations for presence of objectionable microorganisms prior lo distribution. For example. your firm produced drug products for office use between January and March, 2022 for the following:
• Tetracaine 6% Topical Solution
• Profound Easy Oral Gel
• Skin Renew, Medical. Benzo/Lido/'Tetra, 6/6/4% Cream
• Benzocaine 20% SUSP
• 8enzo/Lido Tetra, 20/5/10% Ointment
None of these drug products were tested for presence of objectionable microorganisms.
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically,
Your firm failed to conduct appropriate tests to determine the identity and strength of each active ingredient in non-sterile drug products produced for offices use prior to release and distribution. for example. your firm produced drug products for office use between January and March, 2022 for the following:
• Tetracaine 6% Topical Solution
• Profound Easy Oral Gel
• Skin Renew Medical. Benzo/Lido/Tetra, 6/6/4% Cream
•Benzocaine 20% SUSP
• Benzo/Lido/Tetra. 20/5/10% Ointment
You did not conduct assay or other appropriate tests for these drugs.
Observation 6
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
Observation 7
The calibration of instruments is not done at suitable intervals with provisions for remedial action in the event accuracy and/or precision limit:s are not met.
Specifically.
Your firm calibrated the balance inside the biological safety cabinet using a standard weight <Redacted B4> according to instructions on the Form of 2022 <Redacted B4> Calibration of Balance: however, your calibration did not cover the range of weight of active pharmaceutical ingredients recorded in the logged formula worksheets. For example. your firm used Tetracaine 4.8 g. Prilocaine 6g. Lidocaine HCL 6g. and Phenylephrine HCL 2.4 g to produce Profound Easy Oral Gel, Rx <Redacted B4> on 2/23/2022, and tetracaine 14.4 g to produce terracaine 6% solution. Rx <Redacted B4> on 2/24/2022. This balance has not been calibrated.
State board of pharmacy records
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Mar 4, 2026: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended.”, license PHY 55673, case AC 7930, Lynn Oaks Compounding Pharmacy, Thousand Oaks, CA. Board list
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.